1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades Neurodegenerativas: desarrollo de terapias

Enfermedades Neurodegenerativas: desarrollo de terapias

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Fernández-Ruiz J, Gómez-Ruiz M, García C, Hernández M, Ramos JA.

    Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies.

    METHOD ENZYMOL . 593: 175-198. Nº de citas: 10

    [doi:10.1016/bs.mie.2017.06.021]

  • Lago-Fernandez A, Redondo V, Hernandez-Folgado L, Figuerola-Asencio L, Jagerovic N.

    New Methods for the Synthesis of Cannabidiol Derivatives.

    METHOD ENZYMOL . 593: 237-257. Nº de citas: 3

    [doi:10.1016/bs.mie.2017.05.006]

  • Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, Fernández-Ruiz J, García-Arencibia M, Pazos MR.

    Corrigendum to Biological characterization of PM226, a chromenoisoxazole, as a selective CB 2 receptor agonist with neuroprotective profile [Pharmacol. Res. 110 (August 2016) (2016) 205-215].

    PHARMACOLOGICAL RESEARCH . 120: 302-302.

    [doi:10.1016/j.phrs.2017.04.002]

  • Fernández-Trapero M, Espejo-Porras F, Rodríguez-Cueto C, Coates JR, Pérez-Díaz C, de Lago E, Fernández-Ruiz J.

    Upregulation of CB 2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis.

    DISEASE MODELS & MECHANISMS . 10(5): 551-558. Nº de citas: 33

    [doi:10.1242/dmm.028373]

  • Rodríguez-Cueto C, Hernández-Gálvez M, Hillard CJ, Maciel P, Valdeolivas S, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J.

    Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.

    Plos One . 12(4): . Nº de citas: 4

    [doi:10.1371/journal.pone.0176521]

  • Ceprián M, Jiménez-Sánchez L, Vargas C, Barata L, Hind W, Martínez-Orgado J.

    Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke.

    Neuropharmacology . 116: 151-159. Nº de citas: 45

    [doi:10.1016/j.neuropharm.2016.12.017]

  • Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernández-Ruiz J.

    Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 18(4): . Nº de citas: 18

    [doi:10.3390/ijms18040684]

  • Ragusa G, Gómez-Cañas M, Morales P, Rodríguez-Cueto C, Pazos MR, Asproni B, Cichero E, Fossa P, Pinna GA, Jagerovic N, Fernández-Ruiz J, Murineddu G.

    New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.

    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY . 127: 398-412. Nº de citas: 9

    [doi:10.1016/j.ejmech.2017.01.002]

  • Rodríguez-Cueto C, Hernández-Gálvez M, Hillard CJ, Maciel P, García-García L, Valdeolivas S, Pozo MA, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J.

    DYSREGULATION OF THE ENDOCANNABINOID SIGNALING SYSTEM IN THE CEREBELLUM AND BRAINSTEM IN A TRANSGENIC MOUSE MODEL OF SPINOCEREBELLAR ATAXIA TYPE-3

    Neuroscience . 339: 191-209. Nº de citas: 15

    [doi:10.1016/j.neuroscience.2016.09.046]

  • Navarro G, Morales P, Rodríguez-Cueto C, Fernández-Ruiz J, Jagerovic N, Franco R.

    Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders

    FRONTIERS IN NEUROSCIENCE . 10: 406-406. Nº de citas: 64

    [doi:10.3389/fnins.2016.00406]

  • Palomo-Garo C, Gómez-Gálvez Y, García C, Fernández-Ruiz J.

    Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice

    PHARMACOLOGICAL RESEARCH . 110: 181-192. Nº de citas: 17

    [doi:10.1016/j.phrs.2016.04.004]

  • Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, Fernández-Ruiz J, García-Arencibia M, Pazos MR.

    Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.

    PHARMACOLOGICAL RESEARCH . 110: 205-215. Nº de citas: 17

    [doi:10.1016/j.phrs.2016.03.021]

  • Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos R, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Jagerovic N.

    Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

    JOURNAL OF MEDICINAL CHEMISTRY . 59(14): 6753-6771. Nº de citas: 23

    [doi:10.1021/acs.jmedchem.6b00397]

  • Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E.

    VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.

    SCIENTIFIC REPORTS . 6: 29789-29789. Nº de citas: 44

    [doi:10.1038/srep29789]

  • López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MA, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutierrez S, García-Bermejo ML, Fernández Ruiz J, Guzmán M, García de Yébenes Prous J.

    A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

    JOURNAL OF NEUROLOGY . 263(7): 1390-1400. Nº de citas: 69

    [doi:10.1007/s00415-016-8145-9]

  • García C, Palomo-Garo C, Gómez-Gálvez Y, Fernández-Ruiz J.

    Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia

    BRITISH JOURNAL OF PHARMACOLOGY . 173(13, SI): 2069-2079. Nº de citas: 42

    [doi:10.1111/bph.13215]

  • Deiana V, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Asproni B, Cichero E, Fossa P, Muñoz E, Deligia F, Murineddu G, García-Arencibia M, Pinna GA.

    Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.

    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY . 112: 66-80. Nº de citas: 18

    [doi:10.1016/j.ejmech.2016.02.005]

  • Rubio M, Valdeolivas S, Piscitelli F, Verde R, Satta V, Barroso E, Montolio M, Aras LM, Di Marzo V, Sagredo O, Fernández-Ruiz J.

    Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome.

    Pharmacology research & perspectives . 4(2): . Nº de citas: 10

    [doi:10.1002/prp2.220]